Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)
ID: 340522Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/340522

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-186.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the biological and immunological effects of gender reassignment interventions on HIV and STI susceptibility among transgender individuals. This initiative seeks to address the significant health disparities faced by transgender populations, who are at a notably higher risk of HIV infection, by investigating the physiological changes resulting from gender-affirming therapies. Eligible applicants include a wide range of organizations, with a total funding ceiling of $275,000 available over a two-year period, and applications must be submitted by December 7, 2024. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-186.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-186-Full-Announcement.html
    Please provide the text you would like summarized.
    PAR-22-186.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity titled "Transgender People: Immunity, Prevention, and Treatment of HIV and STIs" (R21 Clinical Trial Not Allowed). This initiative aims to support exploratory research into the biological and immunological effects of interventions used in gender reassignment on HIV and STI susceptibility among transgender individuals. With transgender people facing a significantly increased risk of HIV infection—approximately 49 times higher than other adult populations—the funding seeks to understand the immunological impacts of surgeries and hormone treatments. Applications are invited from diverse organizations, including educational institutions and nonprofits, with a total budget cap of $275,000 over two years. Notably, clinical trials are excluded from this inquiry. The research should focus on the physiological changes induced by gender-affirming therapies and their implications for susceptibility to infections. Interested applicants must adhere to specific registration and submission instructions via Grants.gov and utilize rigorous evaluation criteria, emphasizing innovation, investigator qualifications, and the significance of the proposed aims. This announcement reflects a commitment to addressing health disparities in the transgender community.
    Similar Opportunities
    Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances," aimed at supporting studies that explore the biological mechanisms linking sex hormones, HIV, and substance use disorders (SUD). This initiative encourages exploratory research that elucidates how sex hormones affect HIV replication and addiction behaviors, particularly in populations affected by both HIV and drug addiction, while requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. The funding opportunity allows for grant applications of up to $275,000 over a two-year period, with a submission deadline of March 13, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-008.html.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances." This funding initiative aims to support research that investigates how sex hormones affect the comorbidity of HIV and substance use disorders (SUD), with a focus on identifying biological mechanisms and potential therapeutic targets. The program is particularly significant as it seeks to fill critical knowledge gaps regarding the interactions between sex hormones and HIV outcomes in individuals using addictive substances. Interested applicants can apply for grants with a budget ceiling of $400,000 per year for a maximum project period of five years, and must include a Plan for Enhancing Diverse Perspectives (PEDP) in their applications. The application deadline is March 13, 2025, and further inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)." This initiative aims to support innovative observational and intervention-based research that identifies and characterizes the pathways and mechanisms contributing to health disparities among sexual and gender minority populations, particularly those from marginalized racial, ethnic, and socioeconomic backgrounds. The research is crucial for addressing evidence gaps related to minority stress, resilience, and culturally responsive healthcare, ultimately promoting equitable health outcomes and improving access to care for these communities. Interested applicants can apply for a maximum funding of $500,000 annually for up to five years, with the application deadline set for January 7, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-077.html.
    Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the neuroimmune connections related to HIV and substance use disorders. This initiative seeks to identify and characterize neuroimmune networks and communication pathways, as well as discover novel modulatory tools that can enhance understanding of the regulatory mechanisms contributing to the comorbidity of HIV and substance use disorders. The NIH intends to allocate up to $2 million to fund approximately six awards, with individual budgets not exceeding $275,000 over a two-year period. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer," aimed at supporting pilot and exploratory research. This initiative seeks to investigate the combined effects of cancer and HIV stigma on health outcomes for individuals living with HIV who are also diagnosed with cancer, with a focus on developing stigma reduction interventions and promoting research in regions with high burdens of both diseases. The grant, which has a maximum budget of $275,000 for a duration of up to two years, encourages applications from a diverse range of eligible entities, including educational institutions and community organizations. Interested applicants should note that the application period opens on November 13, 2024, and the submission deadline is December 10, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link provided in the announcement.
    Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity (PA-21-205) aimed at the development and testing of innovative interventions to enhance HIV prevention, treatment, and program implementation for individuals who use drugs. This R34 grant focuses on formative research and pilot studies that assess the feasibility, safety, and acceptability of various interventions, including behavioral, social, and structural approaches, particularly integrating substance use considerations into HIV care. The initiative is crucial in addressing the ongoing challenges of the HIV epidemic among populations significantly impacted by substance use, with projects expected to enhance HIV testing, preventive services, and treatment adherence. Interested applicants can apply for grants with a ceiling of $225,000, and the application deadline is January 7, 2025. For further information, contact the NIH OER Webmaster at grantsinfo@nih.gov or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html.
    Transgender Women’s Interventions: Pilot and Evaluation
    Active
    Centers for Disease Control - NCHHSTP
    The Centers for Disease Control - NCHHSTP is forecasting a funding opportunity titled "Transgender Women’s Interventions: Pilot and Evaluation," aimed at supporting HIV prevention services for transgender women. This cooperative agreement seeks applications from organizations that are embedded within the transgender community and have a proven history of providing HIV prevention services, with the ability to operate in up to three service areas, including those that may cross state lines. The program is critical for addressing health disparities and enhancing the effectiveness of HIV prevention interventions tailored for transgender women. The estimated total program funding is $8,400,000, with eight awards anticipated, and applications must be submitted electronically by 11:59 pm ET on October 9, 2024. For further inquiries, interested applicants can contact Andrea Moore at AMoore@cdc.gov or by phone at 404-639-6262.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.